A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins

Nature Communications

Volumn 6, Issue , 2015, Pages

  Fibriansah, Guntur ^a,b   Tan, Joanne L ^a,b   Smith, Scott A ^c   De Alwis, Ruklanthi ^d   Ng, Thiam Seng ^a,b   Kostyuchenko, Victor A ^a,b   Jadi, Ramesh S ^d   Kukkaro, Petra ^a,b   De Silva, Aravinda M ^d   Crowe, James E ^c,e   Lok, Shee Mei ^a,b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ANTIBODY; MOLECULAR ANALYSIS; PROTEIN; VIRAL DISEASE; VIRUS;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL SURFACE; DENGUE VIRUS 3; ELECTRON MICROSCOPY; HEAVY CHAIN; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; RECEPTOR BINDING; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; CELL MEMBRANE; CHEMISTRY; CHLOROCEBUS AETHIOPS; CRYOELECTRON MICROSCOPY; DENGUE; DENGUE VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE; SEQUENCE HOMOLOGY; SERODIAGNOSIS; SEROTYPE; VERO CELL LINE;

DENGUE VIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; CRYOELECTRON MICROSCOPY; DENGUE; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENOTYPE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; SEQUENCE HOMOLOGY, AMINO ACID; SEROGROUP; VERO CELLS;

EID: 84923347933     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7341     Document Type: Article

References (58)

1. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504-507 (2013).
2. Thomas, S. J. & Endy, T. P. Critical issues in dengue vaccine development. Curr. Opin. Infect. Dis. 24, 442-450 (2011).
3. Higa, Y. Dengue vectors and their spatial distribution. Trop. Med. Health 39, 17-27 (2011).
4. Holmes, E. & Twiddy, S. The origin, emergence and evolutionary genetics of dengue virus. Infect. Genet. Evol. 3, 19-28 (2003).
5. Vasilakis, N. & Weaver, S. C. The history and evolution of human dengue emergence. Adv. Virus Res. 72, 1-76 (2008).
6. Halstead, S. B. Dengue. Lancet 370, 1644-1652 (2007).
7. Imrie, A. et al. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol. 20, 672-675 (2007).
8. Halstead, S. B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60, 421-467 (2003).
9. Kuhn, R. J. et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717-725 (2002).
10. Zhang, X. et al. Cryo-EM structure of the mature dengue virus at 3.5-A resolution. Nat. Struct. Mol. Biol. 20, 105-110 (2013).
11. Kostyuchenko, V. A., Zhang, Q., Tan, J. L., Ng, T. S. & Lok, S. M. Immature and mature dengue serotype 1 virus structures provide insight into the maturation process. J. Virol. 87, 7700-7707 (2013).
12. Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl Acad. Sci. USA 100, 6986-6991 (2003).
13. Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79, 1223-1231 (2005).
14. Zhang, Y. et al. Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618 (2004).
15. Chin, J. F., Chu, J. J. & Ng, M. L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 9, 1-6 (2007).
16. Klein, D. E., Choi, J. L. & Harrison, S. C. Structure of a dengue virus envelope protein late-stage fusion intermediate. J. Virol. 87, 2287-2293 (2013).
17. Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319 (2004).
18. Roehrig, J. T. Antigenic structure of flavivirus proteins. Adv. Virus Res. 59, 141-175 (2003).
19. Gromowski, G. D. & Barrett, A. D. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366, 349-360 (2007).
20. Shrestha, B. et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 6, e1000823 (2010).
21. Sukupolvi-Petty, S. et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81, 12816-12826 (2007).
22. Wahala, W. M., Huang, C., Butrapet, S., White, L. J. & de Silva, A. M. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J. Virol. 86, 4019-4023 (2012).
23. Wahala, W. M., Kraus, A. A., Haymore, L. B., Accavitti-Loper, M. A. & de Silva, A. M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392, 103-113 (2009).
24. Smith, S. A. et al. The potent and broadly neutralizing human dengue virusspecific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 4, e00873-13 (2013).
25. Costin, J. M. et al. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J. Virol. 87, 52-66 (2013).
26. de Alwis, R. et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl Acad. Sci. USA 109, 7439-7444 (2012).
27. Beltramello, M. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271-283 (2010).
28. Smith, S. A. et al. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J. Virol. 88, 12233-12241 (2014).
29. Teoh, E. P. et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4, 139ra83 (2012).
30. Smith, S. A. et al. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J. Virol. 86, 2665-2675 (2012).
31. Reading, S. A. & Dimmock, N. J. Neutralization of animal virus infectivity by antibody. Arch. Virol. 152, 1047-1059 (2007).
32. Fibriansah, G. et al. Structural changes in dengue virus when exposed to a temperature of 37 degrees C. J. Virol. 87, 7585-7592 (2013).
33. Zhang, X. et al. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc. Natl Acad. Sci. USA 110, 6795-6799 (2013).
34. Watterson, D., Kobe, B. & Young, P. R. Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. J. Gen. Virol. 93, 72-82 (2012).
35. Kaufmann, B. & Rossmann, M. G. Molecular mechanisms involved in the early steps of flavivirus cell entry. Microbes Infect. 13, 1-9 (2011).
36. Pokidysheva, E. et al. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124, 485-493 (2006).
37. Bressanelli, S. et al. Structure of a flavivirus envelope glycoprotein in its lowpH-induced membrane fusion conformation. EMBO J. 23, 728-738 (2004).
38. Fibriansah, G. et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med. 6, 358-371 (2014).
39. Kaufmann, B. et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl Acad. Sci. USA 107, 18950-18955 (2010).
40. Low, J. G. et al. Early dengue infection and outcome study (EDEN)-study design and preliminary findings. Ann. Acad. Med. Singapore 35, 783-789 (2006).
41. Kraus, A. A., Messer, W., Haymore, L. B. & de Silva, A. M. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol. 45, 3777-3780 (2007).
42. Smith, S. A. et al. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis. 207, 1898-1908 (2013).
43. Stiasny, K., Kiermayr, S., Holzmann, H. & Heinz, F. X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80, 9557-9568 (2006).
44. Sukupolvi-Petty, S. et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84, 9227-9239 (2010).
45. Shu, P. Y. et al. Development of group- and serotype-specific one-step SYBR green I-based real-time reverse transcription-PCR assay for dengue virus. J. Clin. Microbiol. 41, 2408-2416 (2003).
46. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001).
47. Tang, G. et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38-46 (2007).
48. Ludtke, S. J., Baldwin, P. R. & Chiu, W. EMAN: semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 128, 82-97 (1999).
49. Liu, X., Jiang, W., Jakana, J. & Chiu, W. Averaging tens to hundreds of icosahedral particle images to resolve protein secondary structure elements using a Multi-Path Simulated Annealing optimization algorithm. J. Struct. Biol. 160, 11-27 (2007).
50. Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
51. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta. Crystallogr. D. Biol. Crystallogr. 66, 486-501 (2010).
52. Trabuco, L. G., Villa, E., Mitra, K., Frank, J. & Schulten, K. Flexible fitting of atomic structures into electron microscopy maps using molecular dynamics. Structure 16, 673-683 (2008).
53. Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781-1802 (2005).
54. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38 27-8 (1996).
55. Jones, T. A., Zou, J. Y. & Cowan, S. W. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119 (1991).
56. Arnold, K., Bordoli, L., Kopp, J. & Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006).
57. Gerstein, M. & Richards, F. M. in International Tables for Crystallography Vol. F (eds Arnold, E., Himmel, D. M. & Rossmann, M. G.) 703-712 (International Union of Crystallography, 2012).
58. Corpet, F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16, 10881-10890 (1988).